JP5881270B2 - Ｎｆａｔの制御因子 - Google Patents

Ｎｆａｔの制御因子 Download PDF

Info

Publication number
JP5881270B2
JP5881270B2 JP2008549576A JP2008549576A JP5881270B2 JP 5881270 B2 JP5881270 B2 JP 5881270B2 JP 2008549576 A JP2008549576 A JP 2008549576A JP 2008549576 A JP2008549576 A JP 2008549576A JP 5881270 B2 JP5881270 B2 JP 5881270B2
Authority
JP
Japan
Prior art keywords
nfat
cells
cell
protein
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008549576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522579A (ja
JP2009522579A5 (enExample
Inventor
アンジャナ ラオ
アンジャナ ラオ
ステファン フェスク
ステファン フェスク
パトリック ホーガン
パトリック ホーガン
ユサン グォーク
ユサン グォーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2009522579A publication Critical patent/JP2009522579A/ja
Publication of JP2009522579A5 publication Critical patent/JP2009522579A5/ja
Application granted granted Critical
Publication of JP5881270B2 publication Critical patent/JP5881270B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008549576A 2006-01-05 2007-01-05 Ｎｆａｔの制御因子 Active JP5881270B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75693406P 2006-01-05 2006-01-05
US60/756,934 2006-01-05
PCT/US2007/000280 WO2007081804A2 (en) 2006-01-05 2007-01-05 Regulators of nfat

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013268702A Division JP2014128267A (ja) 2006-01-05 2013-12-26 Ｎｆａｔの制御因子
JP2014000164A Division JP6025758B2 (ja) 2006-01-05 2014-01-06 Ｎｆａｔの制御因子

Publications (3)

Publication Number Publication Date
JP2009522579A JP2009522579A (ja) 2009-06-11
JP2009522579A5 JP2009522579A5 (enExample) 2010-06-24
JP5881270B2 true JP5881270B2 (ja) 2016-03-09

Family

ID=38256924

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008549576A Active JP5881270B2 (ja) 2006-01-05 2007-01-05 Ｎｆａｔの制御因子
JP2013268702A Withdrawn JP2014128267A (ja) 2006-01-05 2013-12-26 Ｎｆａｔの制御因子
JP2014000164A Active JP6025758B2 (ja) 2006-01-05 2014-01-06 Ｎｆａｔの制御因子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013268702A Withdrawn JP2014128267A (ja) 2006-01-05 2013-12-26 Ｎｆａｔの制御因子
JP2014000164A Active JP6025758B2 (ja) 2006-01-05 2014-01-06 Ｎｆａｔの制御因子

Country Status (5)

Country Link
US (4) US8399185B2 (enExample)
EP (2) EP1984400B1 (enExample)
JP (3) JP5881270B2 (enExample)
CA (1) CA2636417C (enExample)
WO (1) WO2007081804A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984400B1 (en) 2006-01-05 2012-11-28 Immune Disease Institute, Inc. Regulators of nfat
EP2013627A4 (en) * 2006-04-10 2009-08-05 Queens Medical Ct CRAC-MODULATORS AND ITS USE IN THE ACTIVE SUBSTANCE
WO2007139926A2 (en) * 2006-05-26 2007-12-06 The Regents Of The University Of California Crac channel and modulator screening methods
WO2008148108A1 (en) 2007-05-24 2008-12-04 Calcimedica, Inc. Calcium channel proteins and uses thereof
CA2699157A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
GB0800938D0 (en) * 2008-01-18 2008-02-27 Ge Healthcare Uk Ltd Multiplex cell signalling assay
EP2321303B1 (en) 2008-08-27 2019-11-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8394778B1 (en) 2009-10-08 2013-03-12 Immune Disease Institute, Inc. Regulators of NFAT and/or store-operated calcium entry
TW201129379A (en) 2009-11-20 2011-09-01 Amgen Inc Anti-Orai1 antigen binding proteins and uses thereof
WO2012144972A2 (en) * 2010-01-19 2012-10-26 The General Hospital Corporation Methods to inhibit neurodegeneration
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
PT2563776T (pt) 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
KR101204620B1 (ko) 2010-08-06 2012-11-27 가톨릭대학교 산학협력단 혈관 형성 관련 질환 진단용 마커 및 이의 용도
CA2809830C (en) 2010-08-27 2019-09-10 Calcimedica, Inc. Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium
US9567580B2 (en) 2010-10-08 2017-02-14 Anjana Rao Regulators of NFAT and/or store-operated calcium entry
US20140294873A1 (en) * 2011-11-08 2014-10-02 Children Medical Center Corporation Small molecule screen for inhibitors of nfat: ap-1: dna interactions
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015196068A2 (en) * 2014-06-20 2015-12-23 Geisinger Clinic Loss of dyrk1b gene function to inhibit metabolic syndrome including diabetes and hypertension
RS61588B1 (sr) 2014-08-07 2021-04-29 Daiichi Sankyo Co Ltd Anti-orai1 antitelo
JP6366415B2 (ja) * 2014-08-07 2018-08-01 株式会社 資生堂 Ｏｒａｉ３遺伝子発現抑制剤又はＯＲＡＩ３タンパク質の機能抑制剤を含む細胞賦活剤
EP3778595B1 (en) 2015-02-27 2021-08-25 Calcimedica, Inc. Pancreatitis treatment
EP3331525B1 (en) 2015-08-07 2020-10-07 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
KR20200071082A (ko) 2017-10-17 2020-06-18 리젠 파마슈티컬스 소시에떼 아노님 식도암을 치료하기 위한 crac 채널 조절제
WO2019082124A1 (en) 2017-10-26 2019-05-02 Rhizen Pharmaceuticals Sa COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA
BR112020008219A2 (pt) 2017-10-30 2020-10-27 Rhizen Pharmaceuticals Sa moduladores de canal de cálcio ativado por liberação de cálcio para tratar cânceres hematológicos e sólidos
MX2021003094A (es) 2018-09-14 2021-05-12 Rhizen Pharmaceuticals A G Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas.
WO2020141106A1 (en) * 2019-01-03 2020-07-09 Kemijski Institut Engineered externally regulated artificial transcription regulatory system based on engineered nfat
JP2023526505A (ja) 2020-05-20 2023-06-21 カルシメディカ，インク． 急性腎障害を治療するための方法および組成物
US12522589B2 (en) 2020-11-13 2026-01-13 Calcimedica, Inc. Synthesis of CRAC channel inhibitors
CN112458149B (zh) * 2020-12-03 2021-10-08 北京东方百泰生物科技股份有限公司 一种以cd3为靶点的抗体药物对t细胞激活程度的检测方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
CA2148252C (en) 1992-10-30 2007-06-12 Roger Brent Interaction trap system for isolating novel proteins
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
EP0976823A1 (de) 1998-07-22 2000-02-02 Helge Dr. Völkel Rekombinantes Expressions System und Hoch-Durchsatz BioAssay für die therapeutische Anwendung von Calcineurin-A-Alpha, Calcineurin-A-Beta, Calcineurin-A-Gamma, Calcineurin-B und Copper/Zinc-Superoxide Dismutase bzw. zur Identifizierung von Pharmazeutika
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
US6485924B2 (en) 1999-12-07 2002-11-26 Boehringer Ingelheim International Gmbh Method for identifying inhibitors of cytokinesis
US20040219521A1 (en) 2000-01-21 2004-11-04 Tang Y. Tom Novel nucleic acids and polypeptides
CN1177864C (zh) 2000-06-20 2004-12-01 上海市肿瘤研究所 在肝癌组织中具有表达差异的新的人蛋白及其编码序列
WO2002030976A1 (en) 2000-10-11 2002-04-18 The University Of Melbourne Cell control nucleic acids and proteins
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
WO2003052049A2 (en) 2001-07-09 2003-06-26 Incyte Genomics, Inc. Molecules for disease detection and treatment
NZ513755A (en) 2001-08-24 2001-09-28 Ann Rachel Holmes Protein expression system in yeast comprising a vector encoding a heterologous membrane protein and its application in screening for drugs
EP1293569A3 (en) 2001-09-14 2004-03-31 Research Association for Biotechnology Full-length cDNAs
US20050107588A1 (en) * 2001-11-13 2005-05-19 Duggan Brendan M. Receptors and membrane-associated proteins
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
WO2004078995A2 (en) * 2003-03-04 2004-09-16 Neurogenetics, Inc. Methods of modulating and of identifying agents that modulate intracellular calcium
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2008518610A (ja) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
CA2606341A1 (en) 2005-04-29 2006-11-09 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
US7481994B2 (en) 2005-06-07 2009-01-27 The Board Of Trustees Of The Leland Stanford Junior University Calcium biosensor polypeptides and methods of use
WO2007047796A2 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1984400B1 (en) 2006-01-05 2012-11-28 Immune Disease Institute, Inc. Regulators of nfat
EP2013627A4 (en) 2006-04-10 2009-08-05 Queens Medical Ct CRAC-MODULATORS AND ITS USE IN THE ACTIVE SUBSTANCE
WO2007139926A2 (en) 2006-05-26 2007-12-06 The Regents Of The University Of California Crac channel and modulator screening methods
WO2008148108A1 (en) 2007-05-24 2008-12-04 Calcimedica, Inc. Calcium channel proteins and uses thereof
JP5559049B2 (ja) 2007-07-10 2014-07-23 チルドレンズ メディカル センター コーポレーション 間質相互作用分子ノックアウトマウス及びその使用
US20090074750A1 (en) 2007-09-18 2009-03-19 Onn Brandman Regulator of basal cellular calcium concentration and methods of use
JP2011515376A (ja) 2008-03-20 2011-05-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 病的血栓形成に必須であるカルシウムセンサＳＴＩＭ１及び血小板ＳＯＣチャネルＯｒａｉ１（ＣＲＡＣＭ１）
US20120165265A1 (en) 2009-02-26 2012-06-28 Dolmetsch Ricardo E Calcium Signaling Modulators Involving STIM and ORAI Proteins

Also Published As

Publication number Publication date
CA2636417C (en) 2020-08-25
EP1984400A2 (en) 2008-10-29
JP2014128267A (ja) 2014-07-10
JP2009522579A (ja) 2009-06-11
EP2368912B1 (en) 2017-05-03
US9932378B2 (en) 2018-04-03
WO2007081804A2 (en) 2007-07-19
CA2636417A1 (en) 2007-07-19
JP6025758B2 (ja) 2016-11-16
US9163078B2 (en) 2015-10-20
US20180194821A1 (en) 2018-07-12
WO2007081804A3 (en) 2008-03-06
WO2007081804A9 (en) 2007-09-07
EP2368912A1 (en) 2011-09-28
US8399185B2 (en) 2013-03-19
JP2014121327A (ja) 2014-07-03
US20110269174A1 (en) 2011-11-03
EP1984400B1 (en) 2012-11-28
US20090178146A1 (en) 2009-07-09
US20160052981A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
JP6025758B2 (ja) Ｎｆａｔの制御因子
Itoh et al. OATL1, a novel autophagosome-resident Rab33B-GAP, regulates autophagosomal maturation
Renigunta et al. The retention factor p11 confers an endoplasmic reticulum‐localization signal to the potassium channel TASK‐1
Stork et al. Grb2 and the non-T cell activation linker NTAL constitute a Ca2+-regulating signal circuit in B lymphocytes
Wachter et al. Binding of IFT22 to the intraflagellar transport complex is essential for flagellum assembly
Goodchild et al. Access of torsinA to the inner nuclear membrane is activity dependent and regulated in the endoplasmic reticulum
Knapp et al. A longer isoform of Stim1 is a negative SOCE regulator but increases cAMP‐modulated NFAT signaling
Hyndman et al. Multiple functional effects of RET kinase domain sequence variants in Hirschsprung disease
US8809500B2 (en) Complexes comprising mammalian raptor polypeptide and mammalian mTOR polypeptide
Dooley et al. Olfactory receptor signaling is regulated by the post‐synaptic density 95, Drosophila discs large, zona‐occludens 1 (PDZ) scaffold multi‐PDZ domain protein 1
Marble et al. Camguk/CASK enhances Ether-a-go-go potassium current by a phosphorylation-dependent mechanism
Groves et al. An inhibitory role of the G-protein regulator AGS3 in mTOR-dependent macroautophagy
JP4719831B2 (ja) Ｔｐｌ−２／ｃｏｔキナーゼおよび使用方法
Aydın The Role of G-Domain on K-Ras and Gα Dimerization
Wiechmann et al. Competitive inhibitors of Ras effector binding
HK1162534A (en) Regulators of nfat
HK1162534B (en) Regulators of nfat
Hannan Identification of novel protein constituents of the dopamine D2 receptor signalplex: A study of TRPC1/D2R interaction and its role in signalplex trafficking
Chow Novel Regulatory Mechanisms of p115RhoGEF
Zhang The functions of protein phosphatase 5 and Rad17 in DNA damage checkpoint signaling
Krieger A Mass Spectrometry Approach to Identifying Novel Numb-interacting Proteins and Phosphorylation Sites
Rexer Cadherin regulation by tryosine phosphorylation of the catenin p120 and by the p120-like protein ARVCF

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120907

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130828

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20131120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140116

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140523

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160202

R150 Certificate of patent or registration of utility model

Ref document number: 5881270

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250